AR069244A1 - Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica - Google Patents
Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceuticaInfo
- Publication number
- AR069244A1 AR069244A1 ARP080104899A ARP080104899A AR069244A1 AR 069244 A1 AR069244 A1 AR 069244A1 AR P080104899 A ARP080104899 A AR P080104899A AR P080104899 A ARP080104899 A AR P080104899A AR 069244 A1 AR069244 A1 AR 069244A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- effective amount
- therapeutically effective
- proliferative disease
- anticancer agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicacion 1: Un método de tratamiento de una enfermedad proliferativa en un mamífero, que comprende administrarle a un mamífero que padece o está sospechado de padecer la enfermedad proliferativa, una cantidad terapéuticamente eficaz del compuesto de la formula (1) o una sal o solvato farmacéuticamente aceptable del mismo, en donde la cantidad terapéuticamente eficaz es de por lo menos 12 mg por día. Reivindicacion 10: El método de cualquiera de las reivindicaciones 1 a 9, en donde la enfermedad proliferativa es cáncer. Reivindicacion 11: El método de la reivindicacion 10, en donde el cáncer es una leucemia. Reivindicacion 22: El método de cualquiera de las reivindicaciones 1 a 21, que además comprende administrarle al sujeto una cantidad terapéuticamente eficaz de un segundo agente terapéutico. Reivindicacion 23: El método de la reivindicacion 22, en donde el segundo agente terapéutico es un agente anticanceroso. Reivindicacion 24: El método de la reivindicacion 23, en donde el agente anticanceroso se selecciona del grupo que consiste de adriamicina, busulfán, citarabina, ciclofosfamida, dexametasona, fludarabina, fluorouracilo, hidroxiurea, interferones, oblimersen, derivados de platino, taxol, topotecano y vincristina. Reivindicacion 25: El método de la reivindicacion 23, en donde el agente anticanceroso es un inhibidor de la FLT3 quinasa seleccionado del grupo que consiste de PKC 412, MLN 578, CEP-701, CT 53518, CT-53608, CT-52923, D-64406, D-65476, AGL-2033, AG1295, AG1296, KN-1022, PKC-412, SU5416, SU5614, SU11248, L-00021649 y CHIR-258. Reivindicacion 26: El método de cualquiera de las reivindicaciones 1 a 25, que además comprende un paso de diagnostico para determinar la presencia de un FLT3 mutante constitutivamente activo. Reivindicacion 28: El método de la reivindicacion 10, en donde el cáncer es cáncer de vejiga, cáncer de mama, cáncer cervical, cáncer del CNS, cáncer de colon, cáncer de esofago, cáncer de cabeza y cuello, cáncer de hígado, cáncer de pulmon, cáncer nasofaríngeo, cáncer neuroendocrino, cáncer de ovario, cáncer de páncreas, cáncer de prostata, cáncer de rinon, cáncer de las glándulas salivales, cáncer de pulmon de células pequenas, cáncer de piel, cáncer de estomago, cáncer de testículo, cáncer de tiroides, cáncer uterino o formas malignas hematologicas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US258307P | 2007-11-08 | 2007-11-08 | |
| US580307P | 2007-12-07 | 2007-12-07 | |
| US9867608P | 2008-09-19 | 2008-09-19 | |
| US11206008P | 2008-11-06 | 2008-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069244A1 true AR069244A1 (es) | 2010-01-06 |
Family
ID=40262072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104899A AR069244A1 (es) | 2007-11-08 | 2008-11-07 | Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7968543B2 (es) |
| EP (2) | EP2205244B1 (es) |
| JP (2) | JP5645667B2 (es) |
| KR (2) | KR20150105494A (es) |
| CN (1) | CN101835472A (es) |
| AR (1) | AR069244A1 (es) |
| AU (1) | AU2008325141B2 (es) |
| CA (1) | CA2696807C (es) |
| CY (1) | CY1114853T1 (es) |
| DK (1) | DK2205244T3 (es) |
| ES (1) | ES2436266T3 (es) |
| HR (1) | HRP20131083T1 (es) |
| MX (1) | MX2010002396A (es) |
| PL (1) | PL2205244T3 (es) |
| PT (1) | PT2205244E (es) |
| SI (1) | SI2205244T1 (es) |
| TW (1) | TW200924756A (es) |
| WO (1) | WO2009061446A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101448843B (zh) * | 2006-03-17 | 2012-05-09 | 埃姆比特生物科学公司 | 用于疾病治疗的咪唑并噻唑化合物 |
| US8883783B2 (en) * | 2007-09-19 | 2014-11-11 | Ambit Biosciences Corporation | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
| ES2681529T3 (es) | 2009-03-23 | 2018-09-13 | Ambit Biosciences Corporation | Métodos de tratamiento utilizando terapia de combinación |
| US8865710B2 (en) * | 2009-05-14 | 2014-10-21 | Ambit Biosciences Corporation | Methods of treating proliferative diseases |
| KR101819245B1 (ko) | 2009-11-05 | 2018-01-16 | 암비트 바이오사이언시즈 코포레이션 | 이미다조［2,1-ｂ］［1,3］벤조티아졸 유도체의 제조 방법 |
| HUE045270T2 (hu) | 2010-01-05 | 2019-12-30 | Inst Nat Sante Rech Med | FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére |
| UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
| CN103172648B (zh) * | 2011-12-20 | 2016-05-25 | 上海迪诺医药科技有限公司 | 三杂环衍生物、制备方法及应用 |
| JP6116847B2 (ja) * | 2012-10-01 | 2017-04-19 | アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | シクロデキストリンとの混合体を含有する錠剤 |
| WO2015043492A1 (en) * | 2013-09-26 | 2015-04-02 | Sunshine Lake Pharma Co., Ltd. | Substituted urea derivatives and uses thereof in medicine |
| CA2956417C (en) | 2014-07-31 | 2022-09-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Flt3 receptor antagonists |
| EP3237604A2 (en) | 2014-12-22 | 2017-11-01 | Genzyme Corporation | Methods of culturing a mammalian cell |
| TWI711452B (zh) | 2015-02-20 | 2020-12-01 | 日商第一三共股份有限公司 | 癌症的倂用治療法 |
| JP6793401B2 (ja) * | 2015-03-11 | 2020-12-02 | 国立研究開発法人理化学研究所 | 難治性白血病治療薬 |
| EP3254698A1 (en) | 2016-06-08 | 2017-12-13 | Universite De Montpellier | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain |
| AU2018269678A1 (en) | 2017-05-17 | 2019-12-12 | Biodol Therapeutics | FLT3 inhibitors for improving pain treatments by opioids |
| CN113966331B (zh) * | 2020-03-11 | 2024-04-12 | 暨南大学 | 含脲结构的三芳环化合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US233906A (en) * | 1880-11-02 | Combined stirrer and thermometer | ||
| US233903A (en) * | 1880-11-02 | Velocipede | ||
| US994635A (en) * | 1911-01-10 | 1911-06-06 | Harry C Buhoup | Car-truck. |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| CN101448843B (zh) * | 2006-03-17 | 2012-05-09 | 埃姆比特生物科学公司 | 用于疾病治疗的咪唑并噻唑化合物 |
| US8883783B2 (en) * | 2007-09-19 | 2014-11-11 | Ambit Biosciences Corporation | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
-
2008
- 2008-11-07 KR KR1020157024194A patent/KR20150105494A/ko not_active Application Discontinuation
- 2008-11-07 US US12/267,321 patent/US7968543B2/en active Active
- 2008-11-07 PT PT88471131T patent/PT2205244E/pt unknown
- 2008-11-07 CN CN200880112433A patent/CN101835472A/zh active Pending
- 2008-11-07 AR ARP080104899A patent/AR069244A1/es unknown
- 2008-11-07 MX MX2010002396A patent/MX2010002396A/es active IP Right Grant
- 2008-11-07 KR KR1020107006419A patent/KR101578481B1/ko active IP Right Grant
- 2008-11-07 TW TW097143281A patent/TW200924756A/zh unknown
- 2008-11-07 PL PL08847113T patent/PL2205244T3/pl unknown
- 2008-11-07 ES ES08847113T patent/ES2436266T3/es active Active
- 2008-11-07 DK DK08847113.1T patent/DK2205244T3/da active
- 2008-11-07 EP EP08847113.1A patent/EP2205244B1/en active Active
- 2008-11-07 JP JP2010533098A patent/JP5645667B2/ja active Active
- 2008-11-07 AU AU2008325141A patent/AU2008325141B2/en active Active
- 2008-11-07 CA CA2696807A patent/CA2696807C/en active Active
- 2008-11-07 EP EP12197285.5A patent/EP2596795A1/en not_active Withdrawn
- 2008-11-07 SI SI200831093T patent/SI2205244T1/sl unknown
- 2008-11-07 WO PCT/US2008/012539 patent/WO2009061446A1/en active Application Filing
-
2013
- 2013-11-13 HR HRP20131083AT patent/HRP20131083T1/hr unknown
- 2013-11-21 CY CY20131101036T patent/CY1114853T1/el unknown
-
2014
- 2014-06-11 JP JP2014120238A patent/JP2014221765A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2696807C (en) | 2017-11-28 |
| ES2436266T3 (es) | 2013-12-30 |
| US7968543B2 (en) | 2011-06-28 |
| KR101578481B1 (ko) | 2015-12-17 |
| JP2014221765A (ja) | 2014-11-27 |
| KR20150105494A (ko) | 2015-09-16 |
| HRP20131083T1 (hr) | 2013-12-20 |
| EP2205244A1 (en) | 2010-07-14 |
| MX2010002396A (es) | 2010-04-01 |
| TW200924756A (en) | 2009-06-16 |
| EP2596795A1 (en) | 2013-05-29 |
| CN101835472A (zh) | 2010-09-15 |
| PT2205244E (pt) | 2013-11-26 |
| SI2205244T1 (sl) | 2013-12-31 |
| KR20100075853A (ko) | 2010-07-05 |
| EP2205244B1 (en) | 2013-08-21 |
| WO2009061446A1 (en) | 2009-05-14 |
| PL2205244T3 (pl) | 2014-01-31 |
| US20090123418A1 (en) | 2009-05-14 |
| CA2696807A1 (en) | 2009-05-14 |
| AU2008325141B2 (en) | 2014-03-20 |
| DK2205244T3 (da) | 2013-11-25 |
| JP2011503063A (ja) | 2011-01-27 |
| AU2008325141A1 (en) | 2009-05-14 |
| JP5645667B2 (ja) | 2014-12-24 |
| CY1114853T1 (el) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069244A1 (es) | Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica | |
| ES2667958T3 (es) | Crenolanib para el tratamiento de trastornos proliferativos que tienen FLT3 mutado | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| CA3022699A1 (en) | Combination therapy for cancer treatment | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
| HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
| RU2006105652A (ru) | Трициклические ингибиторы парп | |
| CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. | |
| CR9984A (es) | Método de inhibición de cinasa de tirosina cinasa 3 similar a fms | |
| EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
| AR057295A1 (es) | Combinaciones y procedimientos para usar un compuestos de indolinona | |
| AR056321A1 (es) | COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS | |
| JP2011503063A5 (es) | ||
| DOP2013000070A (es) | Combinaciones que contienen n-(2-arilamino)arilsulfonamida sustituida | |
| AU2019315550A1 (en) | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof | |
| CO6382175A2 (es) | Metodo para inhibir la cinasa del c-kit | |
| Favoni et al. | Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma | |
| Benvenuto et al. | (±)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice | |
| RU2013148817A (ru) | Комбинации соединений-ингибиторов акт и мек и способы их применения | |
| JP2024012493A (ja) | 消化管間質腫瘍の治療のための併用療法 | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |